{"product_id":"roiv-bcg-matrix","title":"(ROIV) Roivant Sciences Ltd. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Roivant Sciences Ltd. BCG Matrix helps you quickly assess how the company’s business units or products fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMVT-1402 lead FcRn asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant’s Immunovant stake is a high-beta call on IMVT-1402, a next-gen FcRn antibody in a large autoimmune market. Roivant owned about 76% of Immunovant in FY2025, and the program is aimed at high-unmet-need diseases like Graves’ disease and myasthenia gravis. If clinical data stay clean, it could become a major future value driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrepocitinib lead autoimmune asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrepocitinib is Priovant’s lead autoimmune asset and a dual TYK2\/JAK1 inhibitor, giving it two validated inflammation targets in one molecule.\u003c\/p\u003e\n\u003cp\u003eThat multi-indication optionality matters in biopharma: one late-stage win can support use across more than 1 disease and build a franchise, not just a single product.\u003c\/p\u003e\n\u003cp\u003eIf Phase 3 data stay strong, Brepocitinib can fit the Stars bucket for Roivant Sciences Ltd. because it combines high-growth demand with real upside from a larger addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunovant equity stake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences Ltd. keeps a major economic interest in Immunovant, so it captures upside from the FcRn platform without funding all of the R\u0026amp;D itself. Immunovant’s lead asset, batoclimab, showed an FcRn class effect in 2025 data, and the stock still gives Roivant leveraged exposure to a high-growth area.\u003c\/p\u003e\n\u003cp\u003eThat mix of owned upside and limited capital burden makes this one of Roivant Sciences Ltd.’s clearest Star-type holdings in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePriovant equity stake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoivant’s Priovant stake is a star-like asset because it links Roivant to upside in autoimmune and dermatology programs, where positive data can expand across multiple indications. Priovant is still clinical-stage, so value depends on readouts, but the platform optionality and Roivant’s equity exposure give it leveraged growth potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAutoimmune and dermatology upside\u003c\/li\u003e\n\u003cli\u003eMulti-indication platform optionality\u003c\/li\u003e\n\u003cli\u003eHigh leverage to trial success\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMultiple late stage clinical shots\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoivant Sciences Ltd. ended fiscal 2025 with several active late-stage clinical programs in immunology and inflammation, so this stays a catalyst-heavy Star profile, not a harvest story yet. The company is still funding high development intensity, which fits Star assets that need capital before cash flow scales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLate-stage shots drive near-term value catalysts.\u003c\/li\u003e\n\u003cli\u003eImmunology and inflammation remain core focus areas.\u003c\/li\u003e\n\u003cli\u003e2025 still looks like build phase, not monetization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoivant’s Autoimmune Stars Could Re-rate Fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences Ltd.’s Stars are its autoimmune bets, led by Immunovant and Priovant, where late-stage data can still re-rate value fast. In FY2025, Roivant owned about 76% of Immunovant, giving leveraged upside to IMVT-1402 while limiting full R\u0026amp;D burden.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eImmunovant\u003c\/td\u003e\n\u003ctd\u003e~76% owned\u003c\/td\u003e\n\u003ctd\u003eStar\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eRoivant’s BCG Matrix maps its pipeline and platforms to spotlight growth bets, cash-generators, and assets to hold or trim.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG matrix for Roivant Sciences Ltd. to spot wins, cash drains, and portfolio gaps at a glance\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Roivant Sciences Ltd., helping users verify key claims fast and make better decisions with less uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTelavant sale $7.1B enterprise value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences Ltd. monetized Telavant in Roche’s $7.1 billion enterprise value deal, turning a non-core asset into a major liquidity event. The transaction delivered a large cash inflow plus equity-linked consideration, making it Roivant Sciences Ltd.’s clearest corporate-level cash cow. In BCG terms, this is classic \"milk the asset\" execution: high value created, then harvested.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermavant sale $1.2B cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences Ltd. sold Dermavant to Organon for $1.2 billion in cash, turning a dermatology asset into immediate liquidity. That is classic cash cow behavior: a mature, monetizable asset was harvested instead of funded longer. The deal gave Roivant a large cash inflow with no equity dilution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyovant monetization relugolix franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoivant monetized Myovant after relugolix reached the market, which is classic cash-cow behavior: sell once growth cools and cash flow becomes predictable. Relugolix is already commercial, with ORGOVYX approved in 2020 and Myfembree in 2021, so the franchise had moved beyond pure R\u0026amp;D risk. That fits a mature asset with visible sales and lower reinvestment needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUrovant monetization vibegron franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoivant’s Urovant\/Vibegron asset fits the \"cash cow\" bucket because Gemtesa is already approved and serves a durable overactive bladder market, so it is easier to harvest than to build. Roivant monetized the franchise instead of funding it for growth, which helped convert an operating asset into capital for newer shots on goal. This kind of exit supports Roivant’s model: recycle mature cash flows into pipeline bets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproved product, lower launch risk\u003c\/li\u003e\n\u003cli\u003eEstablished demand, steady monetization\u003c\/li\u003e\n\u003cli\u003eExit frees capital for pipeline\u003c\/li\u003e\n\u003cli\u003eCash cows fund new growth bets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti billion liquidity base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoivant Sciences Ltd. ended fiscal 2025 with about $4.0 billion of cash, cash equivalents, and marketable securities, giving it a real cash-cow layer in the BCG sense. That liquidity came from asset sales and divestitures, which lowered the need for repeated equity raises and diluted fewer holders. With no meaningful debt load, the balance sheet itself helps fund new bets and platform expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2025 liquidity: about $4.0B\u003c\/li\u003e\n\u003cli\u003eDivestitures boosted cash\u003c\/li\u003e\n\u003cli\u003eLess reliance on dilution\u003c\/li\u003e\n\u003cli\u003eBalance sheet funds growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoivant’s Cash Cows Fuel Its Next Growth Bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences Ltd. cash cows are its monetized late-stage assets, led by Telavant, Dermavant, and Myovant, which converted mature programs into major cash inflows. FY2025 ended with about $4.0 billion in cash, cash equivalents, and marketable securities, so Roivant Sciences Ltd. can fund new bets with less dilution. That is the core BCG cash cow role: harvest mature assets and recycle the proceeds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelavant\u003c\/td\u003e\n\u003ctd\u003e$7.1B EV\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDermavant\u003c\/td\u003e\n\u003ctd\u003e$1.2B cash\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 liquidity\u003c\/td\u003e\n\u003ctd\u003e~$4.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eRoivant Sciences Ltd. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Roivant Sciences Ltd. BCG Matrix preview you see here is the exact same file you’ll receive after purchase. There are no mockups, watermarks, or placeholder pages—just the full, professionally formatted report. Once purchased, the document is ready for immediate download and use. What you preview is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAxovant legacy neuro unit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAxovant was one of Roivant Sciences Ltd.'s early high-profile neuro bets, but its lead Alzheimer’s drug intepirdine failed in Phase 3 in 2017, and the unit never became a durable commercial franchise. That profile fits a Dog in the BCG Matrix: low growth, weak share, and little cash generation. Roivant later shifted capital to newer programs, while the Axovant legacy remains a reminder of a high-burn, low-return asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlyvant legacy immunology unit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlyvant never became a core growth engine for Roivant Sciences Ltd.; public filings do not show it as a separate revenue driver, so its scale stayed too small to matter. Its low strategic fit and limited stand-alone economics made it a Dog in BCG terms, not a market winner. Capital was better directed to higher-priority assets with clearer 2025-2026 value creation paths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnzyvant legacy rare disease unit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnzyvant, Roivant Sciences Ltd.’s legacy rare disease unit, never became a major value creator. In FY2025 terms, it stayed outside Roivant’s main growth lanes, so it fits a Dogs profile: low growth, low share, and little capital pull. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePulmovant legacy respiratory unit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePulmovant fits the \"dogs\" box because Roivant Sciences Ltd. never turned it into a leading pulmonary franchise, and the respiratory path stayed hard to scale. In BCG terms, a non-core unit with weak traction and no clear market lead is a capital drain, not a growth engine.\u003c\/p\u003e\n\u003cp\u003eRespiratory R\u0026amp;D is slow and expensive: late-stage trials often need hundreds of patients and many years, so weak programs can keep burning cash without moving the revenue needle.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeak franchise position\u003c\/li\u003e\n\u003cli\u003eLimited commercial traction\u003c\/li\u003e\n\u003cli\u003eHigh development burden\u003c\/li\u003e\n\u003cli\u003eLow strategic fit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpirovant legacy cystic fibrosis effort\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpirovant never turned its cystic fibrosis work into a market leader, and that matters in a field with only about 105,000 patients worldwide and a small set of expert centers. With Vertex still dominant and the CF space highly technical, Spirovant’s weak commercial odds fit the dog bucket in Roivant Sciences Ltd.'s BCG view.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo approved CF product.\u003c\/li\u003e\n\u003cli\u003eSmall, specialized patient pool.\u003c\/li\u003e\n\u003cli\u003eDominant incumbent competition.\u003c\/li\u003e\n\u003cli\u003eLow return on future spend.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoivant’s Dogs: Legacy Assets with Weak Growth and Cash Returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences Ltd.'s Dogs are legacy, low-share assets with weak cash pull, like Axovant, Alyvant, Enzyvant, Pulmovant, and Spirovant. Axovant’s intepirdine failed Phase 3 in 2017, and Spirovant faced a cystic fibrosis market of about 105,000 patients worldwide, still dominated by Vertex. These units fit low-growth, low-return buckets in FY2025-2026 capital planning.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAxovant\u003c\/td\u003e\n\u003ctd\u003ePhase 3 failure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpirovant\u003c\/td\u003e\n\u003ctd\u003eSmall CF pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMVT-1402 Graves disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGraves disease affects about 1% of the U.S. population and is the leading cause of hyperthyroidism, with women up to 7 to 8 times more likely to develop it. The market is still growing because many patients need better options than antithyroid drugs, radioiodine, or surgery.\u003c\/p\u003e\n\u003cp\u003eIMVT-1402 is still in development and has no commercial sales yet, so it has zero market share today. That makes it a clear Question Mark in Roivant Sciences Ltd.'s BCG Matrix: high-growth potential, but no proven revenue base yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMVT-1402 myasthenia gravis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMVT-1402 sits in an attractive but still contested myasthenia gravis market, with global prevalence often estimated at about 100 to 350 per million people. Roivant Sciences Ltd. has no sales base from this asset yet, so the BCG case is still \"question mark\" rather than \"star.\" It needs clear phase data and a path to approval before it can move up the matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMVT-1402 Sjogren disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSjögren disease affects about 0.5% to 1% of adults, and there is no approved FcRn leader in this area, so IMVT-1402 targets a real unmet need. The upside is clear, but commercial uptake is still unproven because physician adoption, payer coverage, and long-term efficacy data are not yet settled. That puts Roivant Sciences Ltd. in question mark territory: high potential, high uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBrepocitinib non infectious uveitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrepocitinib in non infectious uveitis sits in a specialized inflammatory eye market, but Roivant Sciences Ltd. still needs clear clinical and regulatory proof before it can scale. That keeps it in BCG Matrix Question Marks: high market promise, but high execution risk.\u003c\/p\u003e\n\u003cp\u003eAs of 2026, it remains a development-stage bet, so the value case depends on trial data, safety, and FDA\/EMA feedback rather than current sales. One clean read: no approval means no revenue stream yet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized, high-value eye inflammation niche\u003c\/li\u003e\n\u003cli\u003eStill needs clinical validation\u003c\/li\u003e\n\u003cli\u003eRegulatory risk remains the main hurdle\u003c\/li\u003e\n\u003cli\u003eHigh upside, but not de-risked\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBrepocitinib dermatomyositis and cutaneous sarcoidosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrepocitinib in dermatomyositis and cutaneous sarcoidosis fits a question mark: both are rare autoimmune uses with limited current share, but they can scale if trial data leads to approval. Roivant Sciences Ltd. still has to turn clinical signals into payer-backed uptake, and that step usually decides whether a question mark becomes a star. As of fiscal 2025, the value is still mainly option value, not sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare diseases = low share, high upside.\u003c\/li\u003e\n\u003cli\u003eApproval and uptake still drive value.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoivant’s Question Marks Need Trial Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoivant Sciences Ltd.'s question marks are still pre-revenue assets with upside, but no sales proof yet. IMVT-1402 targets Graves disease, myasthenia gravis, and Sjögren disease, while brepocitinib targets non infectious uveitis, dermatomyositis, and cutaneous sarcoidosis. In fiscal 2025, the value case stayed tied to trial data, approval risk, and payer uptake, not current revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMVT-1402\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eNo sales; phase data needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrepocitinib\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eClinical proof still pending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234944065801,"sku":"roiv-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/roiv-bcg-matrix.webp?v=1785730450","url":"https:\/\/dcfanalyst.com\/products\/roiv-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}